DOTmed June 24, 2024
Insightec has announced a successful $150 million equity financing to further support the company’s development and commercialization of MR-guided high intensity focused ultrasound (HIFU) technology.
Insightec’s proprietary technology, with over 160 systems installed globally, has been utilized in nearly 20,000 commercial applications. The technology is FDA approved for incisionless, immediate treatment of essential tremor and Parkinson’s disease. Earlier this year, Insightec unveiled a new version of its flagship platform, Exablate Neuro, dubbing it Exablate Prime, which offers a new user interface and improved ability to treat essential tremor and other movement disorders.
The investment was led by Fidelity Management & Research Company, with significant contributions from Nexus Neurotech Ventures and Ally Bridge Group. Additional support came from new investors Baillie...
Today's Sponsors
Today's Sponsor